Nov 12, 2025 3:07 PM Eastern Standard Time Stride Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Substantial Losses of Lead Plaintiff Deadline in Class Action Lawsuit Against Stride, Inc. - LRN Share NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF†) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have untilJanuary 12, 2026 to file lead plaintiff ...

UPCOMING DEADLINE: Faruqi & Faruqi Reminds Quanex Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18, 2025 - NXNovember 11, 2025 6:37 PM EST | Source: Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Quanex To Contact Him Directly To Discuss Their OptionsIf you suffered losses in Quanex between December 12, 2024 and September 5, 2025 and would like to discuss your legal ...

Core Viewpoint - A securities class action lawsuit has been filed against James Hardie Industries plc for allegedly misleading investors regarding the company's inventory and demand situation during the Class Period from May 20, 2025, to August 18, 2025 [1][2] Allegations of Misconduct - The complaint claims that James Hardie made false statements about strong demand and normal stock levels while knowing that its North America Fiber Cement distributors were destocking inventory as early as April and May 2025 [2] - As a result, the positive statements made by the company regarding its business operations and prospects were materially misleading and lacked a reasonable basis [2] Lead Plaintiff Process - Investors in James Hardie have until December 23, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3] - The lead plaintiff will act on behalf of all class members and select counsel to represent the class, with the ability to share in any recovery not affected by the decision to serve as a lead plaintiff [3] Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of fraud and corporate misconduct [4]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Incorporated for allegedly making false and misleading statements regarding the expected FDA approval of aficamten, which could impact investor confidence and stock performance [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, with a deadline for participation set for November 17, 2025 [2]. - The complaint alleges that Cytokinetics misled investors by claiming that FDA approval for aficamten was expected in the second half of 2025, while failing to submit a necessary Risk Evaluation and Mitigation Strategy (REMS) [2]. Company Statements - Cytokinetics admitted to not submitting the REMS despite having multiple pre-NDA meetings with the FDA regarding risk mitigation, which indicates that the company's public statements were materially misleading [2]. Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Registered shareholders will receive updates through a portfolio monitoring software at no cost [3]. Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 10, 2025 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased or sold Cepton, Inc. (NASDAQ: CPTN) common stock between July 29, 2024, and January 6, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly [6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Cepton's business and operations [5]. - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5]. - The Board of Directors allegedly failed to explore this offer meaningfully, depriving shareholders of the opportunity to consider the Koito Acquisition [5].

Core Points - Rosen Law Firm is reminding KBR, Inc. investors of the November 18, 2025 deadline to join a securities class action lawsuit related to the company's performance during the Class Period from May 6, 2025, to June 19, 2025 [1][2] Group 1: Class Action Details - Investors who purchased KBR securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3] - The lawsuit alleges that KBR made materially false and misleading statements regarding its partnership with HomeSafe and the ability to fulfill the Global Household Goods Contract, leading to investor damages when the truth was revealed [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]

Core Points - Rosen Law Firm is reminding investors of WPP plc to secure counsel before the December 8, 2025 lead plaintiff deadline for a securities class action lawsuit [2][4] - Investors who purchased WPP American Depositary Shares (ADS) between February 27, 2025, and July 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6] - The lawsuit alleges that WPP provided misleading statements about its media arm's capabilities, which led to significant market share loss and investor damages when the truth was revealed [6] Company Information - WPP plc is facing a class action lawsuit due to allegations of providing materially false and misleading statements regarding its media arm's performance amid macroeconomic challenges [6] - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [5]

Core Viewpoint - A class-action lawsuit has been filed against KBR, Inc. alleging misleading statements to investors prior to the cancellation of a significant military contract, which adversely affected the company's business outlook [1][5]. Group 1: Lawsuit Details - The lawsuit aims to represent investors who acquired KBR securities between May 6, 2025, and June 19, 2025 [1][2]. - The legal action claims that KBR executives provided an overly optimistic outlook on a crucial partnership just before its collapse [2]. Group 2: Contract Cancellation Impact - The lawsuit is linked to the Department of Defense's cancellation of its global household goods contract with HomeSafe Alliance LLC, a joint venture led by KBR, announced on June 20, 2025 [3]. - Following the contract termination, KBR shares dropped over 7% due to the loss of a contract valued at up to $20 billion over a potential nine-year term [3]. Group 3: Misrepresentation Allegations - On May 6, 2025, during its Q1 earnings call, KBR assured investors that the HomeSafe partnership was "strong" and projected a revenue contribution of about $400 million for 2025 [4]. - Just weeks later, on June 19, 2025, HomeSafe revealed that TRANSCOM had terminated the contract due to operational issues, which KBR allegedly knew about but did not disclose to investors [5]. Group 4: Financial Guidance Revision - After the contract termination, KBR revised its low-end 2025 revenue guidance downward by approximately $900 million (-9%) on July 31, 2025, primarily due to the removal of the HomeSafe JV revenue contribution [6]. - KBR management acknowledged operational challenges during the earnings call following the revenue guidance revision [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Avantor, Inc. for alleged violations of federal securities laws, particularly regarding misleading statements about the company's competitive position and financial performance [2][4]. Group 1: Allegations Against Avantor - The complaint alleges that Avantor and its executives made false and misleading statements about the company's competitive positioning, which was weaker than publicly represented [4]. - It is claimed that Avantor was negatively affected by increased competition, which was downplayed by the company's executives [4][5]. - The executives' representations about the company's business operations and prospects were materially false and lacked a reasonable basis [4]. Group 2: Financial Performance and Stock Impact - On April 25, 2025, Avantor reported disappointing Q1 2025 results, cutting its guidance and announcing the resignation of CEO Michael Stubblefield, leading to a stock price decline of over 16.5% [6]. - The company reported further disappointing Q2 2025 results on August 1, 2025, with a projected organic revenue growth of -2% to 0%, causing a stock price drop of more than 15% [7]. - On October 29, 2025, Avantor disclosed weak Q3 2025 results, including a net loss of $712 million and -5% organic revenue growth, resulting in a stock price decline of over 23% [8].